



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 18th October, 2017

**To,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Rotunda Bldg, Dalal Street,
Mumbai- 400 051**

Sub: Submission of Statement of Investors Complaints
Scrip Code: 524689

Dear Sir/ Ma'am,

The Statement of Investors Complaints for the Quarter ended 30th September, 2017 in accordance with Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:-

| S. No. | No. of investor complaints pending at the beginning of quarter | No. of investor complaints received during the quarter | No. of investor complaints disposed off during the quarter | No. of investor complaints those remaining unresolved at the end of the quarter |
|--------|--|--|--|---|
| 1. | NIL | NIL | NA | NIL |

This is for the intimation of Exchange and members thereof.

You are requested to take the same on record.

Thanking You
Yours Sincerely

For Parenteral Drugs (India) Limited

Adadhana
Company Secretary



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F



www.jas-anz.org/register